NCT03602651 (STRESS2) is a clinical trial of Hamilton-anxiety scale (HAM-A) in Anxiety Disorders, sponsored by Laboratoire Dielen.

Who is sponsoring NCT03602651?

NCT03602651 is sponsored by Laboratoire Dielen.

What drugs are being tested in NCT03602651?

Interventions in NCT03602651: Hamilton-anxiety scale (HAM-A).

What condition does NCT03602651 study?

NCT03602651 studies Anxiety Disorders.

Is NCT03602651 still recruiting?

NCT03602651 is currently completed. Last updated 20 August 2021.

Last reviewed 2021-08-20 · How we verify

NCT03602651: STRESS2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MAGZEN® Effect on Recent Anxiety Reaction

Completed Last updated 20 August 2021

What this trial tests

trial testing Hamilton-anxiety scale (HAM-A) in Anxiety Disorders in 110 participants. Completed in 14 May 2021.

Timeline

8 November 2019

Primary endpoint
3 May 2021

14 May 2021

Quick facts

Lead sponsor	Laboratoire Dielen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	110
Start date	8 November 2019
Primary completion	3 May 2021
Estimated completion	14 May 2021
Sites	1 location across France

Drugs / interventions tested

Hamilton-anxiety scale (HAM-A)

Conditions studied

Anxiety Disorders — all drugs for Anxiety Disorders →

Sponsor

Laboratoire Dielen

Who can join

Adults 18 to 70, any sex, with Anxiety Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multicentres, observational study, prospective, to evaluate the effect of MAGZEN® in the treatment of recent anxiety reaction.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice.
Oddoux S, Violette P, Cornet J, Akkoyun-Farinez J, et al · · 2022 · cited 7× · PMID 35745154 · DOI 10.3390/nu14122425

Verify or expand the search:

Other recruiting trials for Anxiety Disorders

Currently open trials in the same condition.

NCT07340281 — Biomarkers for Exercise · NA · recruiting
NCT07432945 — In Vivo Exposure vs. Videochat-Based Vicarious Exposure · NA · recruiting
NCT07316374 — AI Chatbots for Anxiety Mental Health Literacy · NA · active not recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03602651 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratoire Dielen
Last refreshed: 20 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03602651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing